Tech Company Financing Transactions

bluebird bio Funding Round

On 4/20/2011, bluebird bio received $30 million in Series C funding from Arch Venture Partners, Easton Capital and Forbion Capital Partners.

Transaction Overview

Company Name
bluebird bio
Announced On
4/20/2011
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors

Arch Venture Partners (Steven Gillis)

Easton Capital

Forbion Capital Partners (Geert-Jan Mulder)

Third Rock Ventures (Robert Tepper)

TVM Capital (Axel Polack)

Proceeds Purpose
The funds will be used to focus on driving forward the company's clinical trials while strategically investing in its pipeline and core product platform capabilities.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
60 Binney St.
Cambridge, MA 02142
USA
Phone
(339) 499-9300
Website
www.bluebirdbio.com
Email Address
[email protected]
Overview
bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.
Profile
bluebird bio LinkedIn Company Profile
Social Media
bluebird bio Company Twitter Account
Company News
bluebird bio News
Facebook
bluebird bio on Facebook
YouTube
bluebird bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nick Leschly
  Nick Leschly LinkedIn Profile  Nick Leschly Twitter Account  Nick Leschly News  Nick Leschly on Facebook
Chief Financial Officer
Jeffrey Walsh
  Jeffrey Walsh LinkedIn Profile  Jeffrey Walsh Twitter Account  Jeffrey Walsh News  Jeffrey Walsh on Facebook
Chief Medical Officer
David Davidson
  David Davidson LinkedIn Profile  David Davidson Twitter Account  David Davidson News  David Davidson on Facebook
Chief Scientific Officer
Philip Gregory
  Philip Gregory LinkedIn Profile  Philip Gregory Twitter Account  Philip Gregory News  Philip Gregory on Facebook
Chief Technical Officer
Derek Adams
  Derek Adams LinkedIn Profile  Derek Adams Twitter Account  Derek Adams News  Derek Adams on Facebook
VP - Bus. Development
Joanne Smith-Farrell
  Joanne Smith-Farrell LinkedIn Profile  Joanne Smith-Farrell Twitter Account  Joanne Smith-Farrell News  Joanne Smith-Farrell on Facebook
VP - General Counsel
Jason Cole
  Jason Cole LinkedIn Profile  Jason Cole Twitter Account  Jason Cole News  Jason Cole on Facebook
VP - Human Resources
Kathy Wilkinson
  Kathy Wilkinson LinkedIn Profile  Kathy Wilkinson Twitter Account  Kathy Wilkinson News  Kathy Wilkinson on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/20/2011: CrowdOptic venture capital transaction
Next: 4/20/2011: Selexys Pharmaceuticals venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.